Stay updated on Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial page
- Check3 days agoChange DetectedAdded a comprehensive Locations section listing multiple site locations (California, Connecticut, Florida, Indiana, Kansas, Louisiana, Massachusetts, Michigan, North Carolina, Pennsylvania, South Carolina, Tennessee, Texas, and Miyagi, Japan) and replaced previous location groupings with Revision: v3.3.3.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing v3.2.0 in the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check40 days agoChange DetectedThe page no longer displays the general funding/status notice about government operations, while the study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check61 days agoChange DetectedScreenshots show only minor UI adjustments on the page. The core study information such as title, eligibility criteria, outcomes, and locations appears unchanged.SummaryDifference0.3%

- Check83 days agoChange DetectedMajor update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.SummaryDifference3%

- Check90 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%

Stay in the know with updates to Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + Brentuximab Vedotin in Hodgkin Lymphoma Clinical Trial page.